Medical Oncology and Immunotherapy, Center for Immuno-Oncology, University Hospital of Siena, Istituto Toscano Tumori, Siena, Viale Mario Bracci n. 16, 53100, Siena, Italy.
Department of Radiology, Euganea Medica Diagnostic Center, Padua, Italy.
Cancer Immunol Immunother. 2018 Aug;67(8):1317-1324. doi: 10.1007/s00262-018-2191-3. Epub 2018 Jun 26.
Treatment of malignant pleural mesothelioma (MPM) represents a highly unmet medical need. Here, we discuss the results and therapeutic potential of first- and second-generation immunomodulatory antibodies targeting distinct immune checkpoints for the treatment of MPM, as well as their prospective therapeutic role in combination strategies. We also discuss the role of appropriate radiological criteria of response for MPM and the potential need of ad hoc criteria of disease evaluation in MPM patients undergoing treatment with immunotherapeutic agents.
恶性胸膜间皮瘤（MPM）的治疗存在高度未满足的医疗需求。本文讨论了针对不同免疫检查点的第一代和第二代免疫调节抗体在 MPM 治疗中的结果和治疗潜力，以及它们在联合治疗策略中的潜在治疗作用。我们还讨论了 MPM 的适当影像学缓解标准的作用，以及在接受免疫治疗药物治疗的 MPM 患者中，可能需要制定专门的疾病评估标准。
